Skip to content

Study · Non-randomized trial · n = 18 · 1989

3 results

A randomized, placebo-controlled, double-blind study evaluating the efficacy of leuprolide acetate depot in the treatment of uterine leiomyomata.

Friedman AJ, Harrison-Atlas D, Barbieri RL, Benacerraf B, Gleason R, Schiff I

Fertility and sterility1 Feb 1989Cited by 101 (Europe PMC)

PMID2492232 (opens in a new tab)DOI10.1016/s0015-0282(16)60486-7 (opens in a new tab)PepBankPUB-02492232
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In women with leiomyomata, uterine volume decreased significantly from 505 to 305 cu cm after 12 weeks of leuprolide.

    In plain wordsIn women with fibroids, uterine volume decreased from 505 to 305 cu cm after 12 weeks of leuprolide.

    Peptide
    Leuprolide
    Outcome
    DecreaseUterine volume at 12 weeks
    Study

    n = 18

    Comparator
    Pretreatment
    Outcome group
    Uterine Volume · Reproductive and sexual health
    Studied dose
    3.75 mg every 4 weeks · intramuscular · 12 weeksAs given in this study (human).

    Measurements

    Uterine volume
    505 cu cm
    pretreatment
    Uterine volume
    305 cu cm
    12 weeks

    Source sentences

    Summary
    Group A patients had a mean reduction in pretreatment uterine volume from 505 +/- 93 cu cm (mean +/- standard error of the mean) to 305 +/- 57 cu cm after 12 weeks (P less than 0.05 versus pretreatment) and 307 +/- 57 cu cm after 24 weeks of therapy (P less than 0.05 versus therapy (P less than 0.05…
    2 context sentences
    Summary · context
    Thirty-eight premenopausal women with uterine leiomyomata were enrolled in a randomized, double-blind, placebo-controlled study evaluating the efficacy of depot leuprolide acetate (LA), a gonadotropin-releasing hormone agonist, in decreasing uterine volume.
    Summary · context
    Eighteen women received intramuscular (IM) depot LA 3.75 mg every 4 weeks for 24 weeks (group A); 20 women received IM placebo with the same injection schedule (group B).
  2. 02HumanNon-randomized trialEfficacy outcome

    In women with leiomyomata, uterine volume decreased significantly from 505 to 307 cu cm after 24 weeks of leuprolide.

    In plain wordsIn women with fibroids, uterine volume decreased from 505 to 307 cu cm after 24 weeks of leuprolide.

    Peptide
    Leuprolide
    Outcome
    DecreaseUterine volume at 24 weeks
    Study

    n = 18

    Comparator
    Pretreatment
    Outcome group
    Uterine Volume · Reproductive and sexual health
    Studied dose
    3.75 mg every 4 weeks · intramuscular · 24 weeksAs given in this study (human).

    Measurements

    Uterine volume
    505 cu cm
    pretreatment
    Uterine volume
    307 cu cm
    24 weeks

    Source sentences

    Summary
    Group A patients had a mean reduction in pretreatment uterine volume from 505 +/- 93 cu cm (mean +/- standard error of the mean) to 305 +/- 57 cu cm after 12 weeks (P less than 0.05 versus pretreatment) and 307 +/- 57 cu cm after 24 weeks of therapy (P less than 0.05 versus therapy (P less than 0.05…
    2 context sentences
    Summary · context
    Thirty-eight premenopausal women with uterine leiomyomata were enrolled in a randomized, double-blind, placebo-controlled study evaluating the efficacy of depot leuprolide acetate (LA), a gonadotropin-releasing hormone agonist, in decreasing uterine volume.
    Summary · context
    Eighteen women received intramuscular (IM) depot LA 3.75 mg every 4 weeks for 24 weeks (group A); 20 women received IM placebo with the same injection schedule (group B).
  3. 03HumanNon-randomized trialEfficacy outcome

    In women with leiomyomata, uterine volume increased significantly to 446 cu cm at 3 months after leuprolide cessation.

    In plain wordsIn women with fibroids, uterine volume increased to 446 cu cm at 3 months after leuprolide cessation.

    Peptide
    Leuprolide
    Outcome
    IncreaseUterine volume after cessation
    Study

    n = 18

    Comparator
    Week 24
    Outcome group
    Uterine Volume · Reproductive and sexual health
    Studied dose
    3.75 mg every 4 weeks · intramuscular · 24 weeksAs given in this study (human).

    Measurements

    Uterine volume
    446 cu cm
    3 months after cessation

    Source sentences

    Summary
    At 3 months after cessation of therapy, the mean uterine volume in group A had increased to 446 +/- 92 cu cm (P less than 0.05 versus week 24).
    2 context sentences
    Summary · context
    Thirty-eight premenopausal women with uterine leiomyomata were enrolled in a randomized, double-blind, placebo-controlled study evaluating the efficacy of depot leuprolide acetate (LA), a gonadotropin-releasing hormone agonist, in decreasing uterine volume.
    Summary · context
    Eighteen women received intramuscular (IM) depot LA 3.75 mg every 4 weeks for 24 weeks (group A); 20 women received IM placebo with the same injection schedule (group B).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.